Natriuretic peptides in common valvular heart disease.
Valvular heart disease, particularly aortic stenosis and mitral regurgitation, accounts for a large proportion of cardiology practice, and their prevalence is predicted to increase. Management of the asymptomatic patient remains controversial. Biomarkers have been shown to have utility in the management of cardiovascular disease such as heart failure and acute coronary syndromes. In this state-of-the-art review, we examine the current evidence relating to natriuretic peptides as potential biomarkers in aortic stenosis and mitral regurgitation. The natriuretic peptides correlate with measures of disease severity and symptomatic status and also can be used to predict outcome. This review shows that natriuretic peptides have much promise as biomarkers in common valvular heart disease, but the impact of their measurement on clinical practice and outcomes needs to be further assessed in prospective studies before routine clinical use becomes a reality.
Steadman
Christopher D
CD
Department of Cardiovascular Sciences, University Hospitals of Leicester, Leicester, UK. cds18@le.ac.uk
Ray
Simon
S
Ng
Leong L
LL
McCann
Gerry P
GP
D001024:Aortic Valve Stenosis / Q000175:diagnosis / Q000209:etiology / Q000378:metabolism*; D015415:Biomarkers / Q000378:metabolism*; D006801:Humans; D008944:Mitral Valve Insufficiency / Q000175:diagnosis / Q000209:etiology / Q000378:metabolism*; D045265:Natriuretic Peptides / Q000502:physiology*; D011237:Predictive Value of Tests; D011379:Prognosis; D012720:Severity of Illness Index
D015415:Biomarkers; D045265:Natriuretic Peptides